ClinicalTrials.gg
CompletedNCT05759962Updated Sep 26, 2023

Phase 1 Study of LQT-1213 in Healthy Adults

A Phase 1 interventional study of LQT-1213 and Placebo in Long QT Syndrome, sponsored by Thryv Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-26.

Sponsored by Thryv Therapeutics, Inc. · Phase 1, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was Mar 2023, 3 years 8 months ago, and no results have been posted to the registry.
  • Registered 3 months after the study started (first participant enrolled Sep 2022, registered Jan 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Long QT Syndrome with a site in United States — 7 open to participants now, 7 under way, 1 of them phase 3. Long QT Syndrome · United States.

Enrollment
12th of 28
50 · median 44
Started
2022
the only one that year
Phase 1
10 of 44
none open now
Registered
40th of 44
by date
Lead sponsor
3 of 44
Thryv Therapeutics, Inc.

Among the 44 studies in Long QT Syndrome with a site in United States, this one is the 12th largest by enrollment of the 28 interventional ones that give a count, is the only one that started in 2022, is one of 10 in phase 1, and was the 40th registered.

Long QT Syndrome

101 studies on the registry are indexed under Long QT Syndrome; 20 are open to participants now.

Browse Long QT Syndrome studies →

Open to participants now

7 of the 44 studies in Long QT Syndrome with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Long QT Syndrome studies recruiting now, 10 (71%) set no upper age limit and 3 (21%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Long QT Syndrome with a site in United States, or all of them as a file.
02

Study summary

This is a single-center, randomized, double-blind, placebo-controlled study to be conducted in 2 parts: single ascending dose (SAD) incorporating a food effect arm and multiple ascending dose (MAD). Potential participants for each part will undergo screening procedures within 28 days of enrollment.

03

Conditions studied

  • Long QT Syndrome

Browse trials for

Keywords

  • LQT-1213
  • Congenital Long QT Syndrome
  • LQTS
  • Serum glucocorticoid regulated kinase-1
  • SGK-1 inhibitor
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Healthy adult male or female participants
  • Females of must agree and commit to use an adequate form of .
  • Men who are biologically capable of fathering children must agree and commit to use an adequate form of contraception.
  • Aged at least 18 years but not older than 60 years (inclusive)
  • (BMI) within 18.0 kg/m\^2 to 32.0 kg/m\^2, inclusively.
  • Non- or ex-smoker
  • Have no diseases captured in the medical history or evidence of clinically significant findings on the physical examination (including vital signs) and/or , as determined by an investigator.

Exclusion Criteria:

  • Clinically significant diseases or any other condition, which, in the opinion of the Investigator, would jeopardize the safety of the participant or impact the validity of the study results.
  • Clinically significant abnormal findings on the physical examination or medical history during screening as deemed by the principal investigator
  • Female who is lactating
  • Female who is pregnant
  • Male participants with a history of oligospermia or azoospermia or any other disorder of the reproductive system
  • Male participants who are undergoing treatment or evaluation for infertility.
  • History of significant to LQT-1213, kinase inhibitors or any related products (including of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs
  • Use of in the 28 days prior to the first study drug administration
  • Maintenance therapy with any drug or significant history of drug dependency or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)
  • Intake of an product or participation in a clinical trial in the 90 days prior to the first study drug administration
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Part A: Single Ascending Dose (SAD) LQT-1213

    In Part A, 4 dosing cohorts will receive a single oral dose of LQT-1213. The highest dose of LQT-1213 to be administered is 1.67 mg/kg.

    Drug: LQT-1213

  • Experimental
    Part A: Food Effect LQT-1213

    In Part A, food effect will be integrated into one of the SAD cohorts as a single dose, two-period with at least a 7-day washout, crossover cohort.

    Drug: LQT-1213

  • Experimental
    Part B: Multiple Ascending Dose (MAD) LQT-1213

    In Part B, 3 dosing cohorts will receive LQT-1213 in the morning on Day 1 and Day 7 and twice daily (BID) on Days 2 to 6.

    Drug: LQT-1213

  • Placebo comparator
    Part A: Single Ascending Dose (SAD) Placebo

    In Part A, 6 dosing cohorts will receive a single oral dose of placebo.

    Other: Placebo

  • Placebo comparator
    Part A: Food Effect Placebo

    In Part A, food effect will be integrated into one of the SAD cohorts as a single dose, two-period with at least a 7-day washout, crossover cohort.

    Other: Placebo

  • Placebo comparator
    Part B: Multiple Ascending Dose (MAD) Placebo

    In Part B, 3 dosing cohorts will receive placebo in the morning on Day 1 and Day 7 and twice daily (BID) on Days 2 to 6.

    Other: Placebo

Interventions

  • DrugLQT-1213

    LQT-1213 is a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor

  • OtherPlacebo

    Matching Placebo

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability: Number of Participants with Adverse Events

    Number of Participants with Adverse Events

    Time frame: Part A SAD: Day 7; Part A Food Effect: Day 15; Part B MAD: Day 16

Secondary outcomes

  1. Plasma Pharmacokinetics of LQT-1213: Tlag

    Initial plasma concentration lag time

    Time frame: Part A SAD: Serially on Day 1; Part A Food Effect: Serially on Day 1 and Day 8

  2. Plasma Pharmacokinetics of LQT-1213: Cmax

    Maximum observed plasma drug concentration

    Time frame: Part A SAD: Serially on Day 1; Part A Food Effect: Serially on Day 1 and Day 8; Part B MAD: Serially on Day 1 and 7

  3. Plasma Pharmacokinetics of LQT-1213: Tmax

    Time to maximum observed plasma drug concentration

    Time frame: Part A SAD: Serially on Day 1; Part A Food Effect: Serially on Day 1 and Day 8; Part B MAD: Serially on Day 1

  4. Plasma Pharmacokinetics of LQT-1213: T1/2

    Terminal phase half-life

    Time frame: Part A SAD: Serially on Day 1; Part A Food Effect: Serially on Day 1 and Day 8; Part B MAD: Serially on Day 1 and 7

  5. Plasma Pharmacokinetics of LQT-1213: AUC0-12, AUC0-T, and AUC0-∞=

    Area under the plasma drug concentration versus time curve

    Time frame: Part A SAD: Serially on Day 1; Part A Food Effect: Serially on Day 1 and Day 8; Part B MAD: Serially on Day 1

  6. Plasma Pharmacokinetics of LQT-1213: CL/F

    Clearance, parent only

    Time frame: Part A SAD: Serially on Day 1; Part A Food Effect: Serially on Day 1 and Day 8; Part B MAD: Serially on Day 1

  7. Plasma Pharmacokinetics of LQT-1213: Vz/F

    Volume of distribution, parent only

    Time frame: Part A SAD: Serially on Day 1; Part A Food Effect: Serially on Day 1 and Day 8; Part B MAD: Serially on Day 1

  8. Plasma Pharmacokinetics of LQT-1213: λz

    Terminal elimination rate constant

    Time frame: Part A SAD: Serially on Day 1; Part A Food Effect: Serially on Day 1 and Day 8

  9. Urine Pharmacokinetics of LQT-1213: Ae

    Amount of the administered dose recovered over the entire 24-hour interval

    Time frame: Part A SAD and Food Effect: Serially on Day 1; Part B MAD: Serially on Days 1, 2, 7 and 8

  10. Urine Pharmacokinetics of LQT-1213: Ae0-t

    Amount excreted unchanged in urine over a given time interval

    Time frame: Part A SAD and Food Effect: Serially on Day 1; Part B MAD: Serially on Days 1, 2, 7 and 8

  11. Urine Pharmacokinetics of LQT-1213: Fe

    Percentage of the administered dose recovered over the entire 24-hour interval

    Time frame: Part A SAD and Food Effect: Serially on Day 1; Part B MAD: Serially on Days 1, 2, 7 and 8

  12. Urine Pharmacokinetics of LQT-1213: Fe/F

    Fraction of dose excreted in urine

    Time frame: Part A SAD and Food Effect: Serially on Day 1; Part B MAD: Serially on Days 1, 2, 7 and 8

  13. Urine Pharmacokinetics of LQT-1213: CLR

    Renal clearance Ae0-t/AUC0-t

    Time frame: Part A SAD and Food Effect: Serially on Day 1; Part B MAD: Serially on Days 1, 2, 7 and 8

  14. Plasma Pharmacokinetics of LQT-1213: Ctrough

    Concentration of drug in the blood immediately before the next dose is administered

    Time frame: Part B MAD: Days 3-6

  15. Plasma Pharmacokinetics of LQT-1213: Cmin

    Minimum observed plasma drug concentration

    Time frame: Part B MAD: Day 7

  16. Plasma Pharmacokinetics of LQT-1213: AUC0-tau, AUC0-T, and AUC0-∞

    Area under the plasma drug concentration versus time curve

    Time frame: Part B MAD: Day 7

  17. Plasma Pharmacokinetics of LQT-1213: CL/Fss

    Clearance, parent only

    Time frame: Part B MAD: Day 7

  18. Plasma Pharmacokinetics of LQT-1213: Vz/Fss

    Volume of Distribution, parent only

    Time frame: Part B MAD: Day 7

  19. Plasma Pharmacokinetics of LQT-1213: Rac(AUC) and Rac(Cmax)

    Drug accumulation ratio

    Time frame: Part B MAD: Day 7

07

Study locations

1 site
  • Altasciences Clinical Los Angeles, Inc.
    Cypress, California 90630, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2022 to primary completion in Mar 2023, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2023
First posted
Mar 8, 2023
StartActual
Sep 14, 2022
Primary completionActual
Mar 5, 2023
CompletionActual
Mar 5, 2023
Last update
Sep 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05759962
Lead sponsor
Thryv Therapeutics, Inc.
Responsible party
Sponsor
First posted
Mar 8, 2023
Start date
Sep 14, 2022
Primary completion
Mar 5, 2023
Completion
Mar 5, 2023
Last update
Sep 26, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion